A landmark week across oncology, with pivotal data in lung, prostate, bladder, and haematological cancers reshaping treatment paradigms in both early and advanced disease. Gene editing, RNA therapeutics, and AI drug discovery attracted major capital commitments. Kidney disease emerged as a strategic battleground. A persistent US drug pricing gap versus other high-income countries remained unresolved.

Pharma Phriday (May 8, 2026): The first PROTAC approval validates protein degradation as a therapeutic modality. M&A activity reshapes rare disease, oncology, and immunology, with deals reflecting platform-building over single-asset bets. The immune reset concept attracted significant investment. AI-driven biomarker discovery is becoming standard in late-stage oncology. Positive data landed across underserved indications. Chinese biotech innovation continues to attract Wester

Pharma Phriday (May 1, 2026): A week of bold dealmaking and standout clinical milestones, including a landmark gene-editing readout. AI momentum continued with another high-value partnership. Regulators delivered unusually wide-ranging decisions, including a serious alleged trial-fraud case. Major acquisitions reshaped rare disease, oncology and neuroscience, alongside UK reform and early sales data for a new obesity drug.

This week’s Pharma Phriday (April 24, 2026) covers major AI platform launches and enterprise partnerships, showing AI is expanding beyond drug discovery into wider roles. Clinical trials in respiratory, haematology, and neurology had mixed results, while regulators approved products in vaccines, immunology, oncology, and infectious disease. The industry saw notable consolidation with several multi-billion dollar acquisitions in gene therapy, regenerative medicine, and biosimi

JnJ, Legend expanding cell therapy capacity.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...